Why This Fund Just Made a $55 Million Bet on Dianthus
A prominent fund has poured roughly $55 million into Dianthus as the stock climbs 350%. This article breaks down what...
Biotech
Biotech insights await. This page curates 5 articles on Tempus, Moderna, Praxis, ImmunityBio and market moves to help you evaluate stocks and sharpen your portfolio strategy.
119 articlesAlumis Stock Soared 400%: Cormorant Buys Another $8M
A sharp rise in Alumis shares coincides with a fresh stake from Cormorant Asset Management. This article breaks down ...
China Tech Fund Opens a Biotech Position — What It Signals
A china tech fund opens a biotech position, signaling a broader shift toward life sciences within tech-driven portfol...
Bicara Stock 50% Jump: A Biotech Bet Hits 29%
A sharp move in bicara stock 50% has spotlighted a bold biotech bet that now accounts for nearly a third of one inves...
Nexgel (NXGL) 2026 Earnings Outlook for Investors Today
Nexgel's Q1 2026 earnings reveal the early trajectory of the year. This analysis breaks down the numbers, explains th...
What Know About This Fund’s Exit From Ascendis Pharma
A notable fund liquidated its entire Ascendis Pharma stake, signaling a strategic rotation in a volatile biotech sect...
Fennec (FENC) 2026 Earnings: Q1 Outlook and Takeaways
Investors eye the Fennec Q1 2026 call to gauge milestones, cash runway, and potential catalysts. This guide breaks do...
Reasons Into Hantavirus-Related Biotech: 3 Cautions
A hantavirus outbreak can spark biotech chatter, but three solid realities—limited demand, tough development paths, a...
Verrica (VRCA) 2026 Earnings Outlook and Strategic Plan
Analysts watch Verrica's 2026 earnings for clues on VP-102 sales, cash runway, and pipeline progress. This guide brea...
This Million Shows Growing Confidence in 10x Genomics
A hedge fund recently boosted its position in 10x Genomics, highlighting growing confidence in the biotech tools make...
Halozyme (Halo) 2026 Earnings: A Practical Investor Guide
Halozyme’s halo (HALO) 2026 earnings landscape hinges on ENHANZE collaborations, pipeline milestones, and disciplined...
Tiny Biotech Just Beat AbbVie's Drug: Risk for Investors?
A tiny biotech just beat AbbVie's blockbuster in early-stage results, prompting fresh questions about the durability ...